Progress in Chimeric Antigen Receptor-Modified Natural Killer Cells for Multiple Myeloma.
10.3881/j.issn.1000-503X.14785
- Author:
Wen-Jiao TANG
1
;
Yan LI
1
;
Yu-Huan ZHENG
1
;
Li ZHANG
1
;
Ting NIU
1
Author Information
1. Department of Hematology,Institute of Hematology,West China Hospital,Sichuan University,Chengdu 610041,China.
- Publication Type:Journal Article
- Keywords:
chimeric antigen receptor-modified natural killer cells;
multiple myeloma;
refractory;
relapsed;
treatment
- MeSH:
Animals;
Receptors, Chimeric Antigen/metabolism*;
Multiple Myeloma/metabolism*;
Killer Cells, Natural/metabolism*;
Immunotherapy, Adoptive/methods*;
Tumor Microenvironment
- From:
Acta Academiae Medicinae Sinicae
2023;45(2):290-297
- CountryChina
- Language:Chinese
-
Abstract:
Although the development of novel drugs has significantly improved the survival of patients with multiple myeloma (MM) over the past decades,the lack of effective therapeutic options for relapsed and refractory MM results in poor prognosis.The chimeric antigen receptor (CAR) T-cell therapy has achieved considerable progress in relapsed and refractory MM.Nevertheless,this therapy still has limitations such as cytokine release syndrome,neurotoxicity,and off-target effects.Natural killer (NK) cells,as a critical component of the innate immune system,play an essential role in tumor immunosurveillance.Therefore,CAR-modified NK (CAR-NK) cells are put forward as a therapeutic option for MM.The available studies have suggested that multiple targets can be used as specific therapeutic targets for CAR-NK cell therapy and confirmed their antitumor effects in MM cell lines and animal models.This review summarizes the anti-tumor mechanisms,biological characteristics,and dysfunction of NK cells in the MM tumor microenvironment,as well as the basic and clinical research progress of CAR-NK cells in treating MM.
